Engflag

Recofast PLUS

Quick links to important sections

Recofast PLUS

Recofast PLUS_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Recofast PLUS

What Type of Medicine is Recofast PLUS?

Recofast PLUS is a Fixed-Dose Combination (FDC) pharmaceutical preparation that integrates multiple distinct active substances into a single unit for the management of upper respiratory symptoms in adults and adolescents. This compound drug is typically produced for oral administration as a synthetic oral solid (such as a tablet) or an oral liquid (such as a syrup). The FDC structure is intended to simplify treatment regimens for individuals experiencing multiple overlapping symptoms.

Active Ingredients and Pharmacological Group

The composition of Recofast PLUS is defined by three core pharmacological classes of synthetic active agents. These include:

  • Paracetamol (Acetaminophen): A non-opioid analgesic and antipyretic agent.
  • Phenylephrine or Pseudoephedrine: A sympathomimetic decongestant.
  • Chlorpheniramine or Triprolidine: An H1-receptor antagonist antihistamine.

This three-component combination is formulated to address the various clinical signs associated with the common cold and flu-like syndromes.

General Purpose and Triple-Action Effect

The general purpose of Recofast PLUS is to offer relief from symptomatic discomforts, such as fever, headache, and nasal congestion. This is achieved through a triple-action effect:

  • The Paracetamol component provides analgesia and antipyresis (pain and fever reduction).
  • The decongestant facilitates vasoconstriction to help reduce nasal congestion.
  • The antihistamine performs histamine blockade to manage symptoms such as sneezing and a runny nose (rhinorrhea).

The formulation is intended for those seeking consolidated support to improve physical comfort while the body recovers from the underlying condition.

What side effects are possible with Recofast PLUS?

Possible Side Effects and Safety Information

Official Adverse Reaction Profile

The safety profile of Recofast PLUS, a combination of Paracetamol, an antihistamine, and a decongestant, is officially documented based on the known effects of its components. Reactions are generally classified according to System-Organ Classes (SOC) and frequency bands, ranging from Common to Rare events, as specified in regulatory documents.

Frequency-Classified Effects

Adverse reactions associated with the antihistamine component, such as drowsiness (somnolence), dry mouth, and dizziness, are frequently listed as Common. Effects related to the decongestant, including nervousness, insomnia, palpitations, and increased blood pressure, are also commonly documented. Other effects, such as difficulty passing urine (urinary retention), are officially noted.

Serious Adverse Reactions and Safety Constraints

Regulatory documents emphasize the risk of severe liver injury (hepatotoxicity) linked to the Paracetamol component, particularly if the maximum daily dose is exceeded. Severe cutaneous adverse reactions (SCARs) and blood dyscrasias are documented as Rare but serious events. The official label strictly mandates that the product must not be taken with any other medicine containing Paracetamol.

Population-Specific Safety Notes

Specific caution is warranted for certain patient groups, as defined in regulatory labeling. Older adults may have an increased susceptibility to central nervous system effects, such as sedation, and to urinary retention. Use is generally contraindicated in patients with severe hepatic impairment due to the risk of liver damage. Caution is also advised for individuals with pre-existing conditions, including severe hypertension, heart disease, or glaucoma.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the officially documented descriptions of overdose and mandated emergency actions as stated in government regulatory sources.

Documented Overdose Presentations

Overdose manifestations relate to the combination product's components. The initial stage may include nausea, vomiting, abdominal pain, and pallor due to the Paracetamol component. Delayed acute liver failure and hepatic necrosis are the critical, life-threatening complications documented in regulatory labels, often manifesting 24 to 48 hours after ingestion.

Regulatory documents also list specific symptoms from the other components, including Central Nervous System (CNS) effects such as drowsiness, excitation, convulsions, and coma, alongside cardiovascular effects such as severe hypertension and tachycardia.

Required Emergency Actions

Seek immediate medical attention for any suspected overdose, even if initial symptoms are mild or absent. This is a mandatory instruction because symptoms may not reflect the severity of potential organ damage, particularly the delayed risk of liver injury from Paracetamol.

The specific antidote, N-acetylcysteine (NAC), is required for the Paracetamol component and is most effective when administered within the first eight hours of ingestion. Supportive and symptomatic treatment, including gastric decontamination and cardiac monitoring, is officially described for managing the effects of the antihistamine and decongestant components. Patients must be urgently referred to a hospital for monitoring of liver function tests and observation.

Individuals with risk factors such as chronic alcoholism or pre-existing liver disease have a documented increased risk of severe poisoning.

Therapeutic Uses of Recofast PLUS

Recofast PLUS is a combination medication generally used to provide integrated symptomatic relief across multiple domains of discomfort that typically cluster during periods of illness or allergy. The combination is commonly used for the symptomatic treatment of the common cold and flu-like syndromes.

It is applied across therapeutic areas involving heightened symptom expression, offering temporary supportive assistance when manifestations interfere with daily stability. The formulation is relevant for managing symptom clusters including pain and fever, nasal and sinus congestion, and allergy-related irritation.

“The medication helps address symptom clusters that may become intense or disruptive, supporting patients during difficult episodes.”

Relief Domains and Patient Benefit

This medication is relevant in clinical settings marked by acute and episodic manifestations such as headaches, body aches, elevated fever, stuffy nose, sinus pressure, sneezing, and runny nose. It helps address these symptoms that may intensify over time, contributing to easing discomfort during periods of heightened symptoms and may assist with maintaining a sense of stability when symptoms are more noticeable. It is applied when short-term symptomatic assistance is needed to ease the overall symptom load.

Quick Fact: Relief for Multi-Symptom Discomfort The formulation is applied across three domains of relief—pain/fever, nasal congestion, and allergic irritation—providing integrated support for overlapping symptoms common during illness.

Regulatory References

  1. NIH ClinicalTrials.gov website

Eligibility and Restrictions for Use

The official regulatory eligibility for Recofast PLUS, a combination product containing Paracetamol, an Antihistamine, and a Decongestant, is determined by the most stringent restrictions across its three components.

Category Official Regulatory Status
Populations for whom use is allowed: Adults and adolescents, typically 12 years of age and older, are the approved age group for tablet/capsule formulations.
Populations for whom use is contraindicated: Patients with severe hepatic impairment, severe hypertension, severe coronary artery disease, narrow-angle glaucoma, or those taking Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days [Source 2.4].
Age-related eligibility rules: Children under 12 years of age are generally not recommended to use adult formulations. Combination cold products are generally not recommended for children under 4 years of age [Source 2.1].
Condition-specific eligibility rules: Use requires caution and/or consultation in patients with non-severe heart disease, diabetes mellitus, hyperthyroidism, prostatic hypertrophy, and severe renal impairment [Source 1.1, 2.4].
Pregnancy and lactation eligibility status: Use is generally not recommended or advised against during both pregnancy and breastfeeding [Source 3.1].

Regulatory documents mandate strict prohibition for individuals with severe cardiovascular or liver disease and recent MAOI use, while non-severe conditions require explicit professional caution prior to use.

What should I know about interactions with other medicines?

The interaction profile of Recofast PLUS is based on the documented effects of its active components (Paracetamol, decongestant, and antihistamine) when combined with other substances.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated, and use is prohibited within 14 days of stopping MAOI therapy due to the severe risk of hypertensive crisis. Use with other Paracetamol-containing products or other sympathomimetic decongestants is also contraindicated to prevent additive toxicity and adverse effects.

Pharmacodynamic and Exposure-Altering Interactions

Documented pharmacodynamic interactions include additive CNS depression when the antihistamine component is combined with alcohol or other CNS depressants (e.g., hypnotics, opioids). The antihistamine may also intensify the action of other anticholinergic drugs. The decongestant component may reduce the efficacy of antihypertensives (like Beta-Blockers) and increase cardiovascular risk when co-administered with Cardiac Glycosides.

Pharmacokinetic interactions officially alter drug exposure. Prolonged daily use of Paracetamol may enhance the anticoagulant effect of Warfarin. The antihistamine component can inhibit the metabolism of Phenytoin, potentially leading to toxicity. Paracetamol absorption speed may be increased by Metoclopramide or Domperidone and decreased by Colestyramine.

Population-Specific Notes

Special consideration is documented for the elderly, where CNS depressant and anticholinergic interactions are officially noted to be more pronounced.

Mechanism of Action

Central Modulation of Thermoregulation and Nociception

The Paracetamol component exerts its primary action by functioning as a selective inhibitor of prostaglandin synthesis, specifically targeting a cyclooxygenase enzyme variant located within the Central Nervous System (CNS), particularly in the hypothalamus and central pain pathways. This mechanism is primarily focused on modulating central signaling patterns within thermoregulatory and nociceptive pathways, in contrast to mechanisms that inhibit peripheral COX-2. By suppressing central Prostaglandin E2 left( PGE2 ight) activity, the drug physiologically resets the hypothalamic temperature set-point, leading to the activation of heat loss mechanisms and subsequent adjustment of core body temperature.

Sympathetic Activation for Vascular Tone Adjustment

The decongestant acts as an agonist on alpha1 -adrenergic receptors found on the smooth muscle lining the blood vessels of the nasal mucosa, initiating a downstream signaling cascade involving Ca^2+ mobilization. This receptor activation causes local vasoconstriction, which physiologically reduces blood flow and limits the accumulation of fluid (edema) in the congested tissue.

Peripheral and Central Histamine Receptor Blockade

The antihistamine is a H1 receptor antagonist or inverse agonist that binds to and inactivates peripheral histamine H1 receptors in the respiratory tract. This action is relevant for processes involving histamine-mediated responses. By blocking H1 receptors, the drug limits histamine's ability to increase capillary permeability and stimulate exocrine glands, which results in the limitation of fluid leakage and glandular activity in the nasal membranes.

Dosage and Administration Information

How to use Recofast PLUS — Administration Guidelines

Recofast PLUS is a Fixed-Dose Combination (FDC) medication that follows specific standardized use patterns.

Administration Scope

Feature Instruction
Route of administration Oral ingestion only, for administration as a solid (tablet/capsule) or liquid (syrup/suspension) formulation.
Dosing schedule (Adults and Children 12 years and older) The typical dose is one to two dosage units every 4 to 6 hours as required. The total daily intake of the Paracetamol component must not exceed 4,000 mg from all sources in a 24-hour period.
Timing in relation to meals The medication may generally be taken with or without food.
Preparation requirements Oral liquid forms, if available, must be accurately measured using the dosage device supplied with the product to ensure proper dose delivery.
Age-group administration rules The product is not intended for use in children under 4 years of age. For children 4 to 12 years of age, specific dosage must be determined by a healthcare professional.
Missed-dose rules If a dose is missed, the next dose should be taken only when scheduled, ensuring the 4 to 6 hour interval is maintained. No double dose should be taken.
Special procedural conditions Use is limited to short-term duration, often specified as no longer than 7 days. Administration must not overlap with any other product containing Paracetamol or other FDC ingredients.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern As-needed basis, every 4 to 6 hours, not exceeding a maximum of four to six administrations in 24 hours (dose-dependent).
Instructional basis Standardized pharmacological guidelines for fixed-dose combinations.
Use-context constraints Administration is confined to short-term use and requires the monitoring of concurrent intake of constituent drugs from other sources.

Resulting Procedural Structure

The administration guidelines establish a precise, time-gated framework. This process involves determining the appropriate unit dose, adhering to the mandatory 4-to-6-hour interval between administrations, and ensuring the total daily limit for Paracetamol is not exceeded. This protocol standardizes the use of the FDC.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Recofast PLUS

The clinical evaluation of Recofast PLUS centers on the study of its fixed-dose combination structure, which was evaluated in research exploring acute upper respiratory conditions. The evidence base consists primarily of Randomized Controlled Trials (RCTs) and systematic reviews. Research examined primary outcomes related to patient-reported severity scores for symptoms such as fever, headache, and congestion in generally healthy adults. Findings describe patterns observed in studies regarding the evolution of symptom intensity and outcomes reflecting daily functioning or activity level.

Comparative Study Design and Findings Assessment

Comparative research exploring short-term symptom changes involved trials where the three-component combination was observed in some studies against a placebo. These trials research describes the specific protocols used to measure changes in symptom severity and functional balance between treatment groups, using data related to patient reporting. This research highlights changes measured during the study period when compared to an inactive substance (placebo).

Study Focus on Follow-up and Duration of Relief

The available research was evaluated in settings that primarily focus on short-term observation. The follow-up durations were limited for the main clinical trials, generally spanning 48 hours to five days. This means there is limited information for long-term outcomes or the sustained nature of the observed symptom patterns beyond the first few days of use. Research has been studied for the resolution of episodic symptoms, but long-term outcomes are not fully established.

Evidence in Specific Patient Populations

The primary clinical evidence for Recofast PLUS applies only to the populations studied, which were mainly healthy adults. Although the research base was studied for use in adolescents, data are still limited for this group compared to adults. Furthermore, studies generally exclude individuals with certain pre-existing chronic conditions, meaning data for older adults or multi-morbid groups remain insufficient.

Research Gaps and Areas of Uncertainty

Beyond limited long-term data, a major gap is the reliance of evidence on patient-reported outcomes describing perceived discomfort (such as symptom diaries and severity scales) rather than objective biological markers. The evidence quality is assessed across studies, and certainty remains low regarding the combination’s use outside the typical healthy adult study group, as results apply only to the populations studied.

Key Studies & References

  1. NIH ClinicalTrials.gov Record: Multicenter Study of Cold Combination Therapy (NCT01389518)

Frequently Asked Questions (FAQ)

Common questions about Recofast PLUS (FAQ)

Q: How quickly can I expect Recofast PLUS to start working?

Studies on products with similar components describe that the onset of symptom relief may begin potentially within 30 minutes to one hour after the medication is taken. However, the time it takes for effects to begin can vary based on the specific formulation and the individual user’s body.

Q: How long does the effect of a single dose of Recofast PLUS typically last?

Official regulatory guidelines for this fixed-dose combination recommend a dosing interval of every 4 to 6 hours. This dosing interval, established in official guidelines, aligns with the typical duration of action documented for the medicine's various components.

Q: Are there any specific lifestyle changes that official sources suggest when taking Recofast PLUS?

Official drug documents note a caution against the use of alcohol while taking the medication. This is because alcohol can increase the central nervous system (CNS) effects, such as drowsiness, due to the antihistamine component.

Q: Can Recofast PLUS affect the results of any common medical tests or lab work?

Official documentation notes that some components in this combination product may potentially interfere with diagnostic procedures. For example, the antihistamine component can sometimes produce false negative results in skin tests conducted for allergies.

Q: Is it possible to have an allergic reaction to Recofast PLUS, and what should I look for?

Official product information states that an allergic reaction is a contraindication for using the drug. Rare but serious events, such as Severe Cutaneous Adverse Reactions (SCARs), have been documented. For any sign of a severe allergic response, consulting a medical professional is recommended.

Q: What kind of evidence is available to support the use of Recofast PLUS?

The evidence base primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews. These studies focus on the short-term observation of how the combination affects patient-reported scores for symptoms like fever, headache, and congestion in generally healthy adults.

Q: Does Recofast PLUS have any known interactions with herbal supplements or vitamins?

Official drug information emphasizes that patients should always inform their healthcare provider about all medicines, vitamins, and herbal supplements they are currently using. This comprehensive disclosure helps manage potential risks from unstudied interactions or adverse effects.

Q: Does Recofast PLUS carry any specific warnings or Black Box warnings in the US or EU?

Regulatory documents require specific warnings regarding the component drugs. This includes a prominent caution about the risk of severe liver injury (hepatotoxicity) linked to the Paracetamol component if the maximum daily dose is exceeded.

Q: Why might a doctor prescribe Recofast PLUS instead of just the original Recofast ingredient?

Recofast PLUS is classified as a Fixed-Dose Combination (FDC) preparation. It is described as providing relief from several discomforts, such as fever, pain, congestion, and sneezing, within a single dosage unit, thus offering integrated, simultaneous symptom management.

Q: What is the difference between an 'interaction' and a 'contraindication' for Recofast PLUS?

A contraindication is an absolute condition, such as severe hypertension or recent MAOI use, that generally prohibits the use of the drug due to the documented risk. An interaction is when a substance, like alcohol, can alter the drug’s effects or risk profile, requiring caution or avoidance.

Q: Why do some people report feeling nervous or having trouble sleeping after taking Recofast PLUS?

Official safety documents list nervousness and insomnia (difficulty sleeping) as Common adverse effects of the combination. This is understood to be due to the mechanism of the decongestant component, which works through sympathetic activation.

Q: What should I do if I accidentally take two doses of Recofast PLUS too close together?

Regulatory safety information warns against exceeding the maximum recommended total daily dose of the Paracetamol component, as this carries a risk of liver injury. Regulatory guidance suggests that the next dose should be taken only when scheduled, ensuring the proper time interval is maintained.

Q: Is Recofast PLUS designed to be taken for a short period or is it for long-term use?

Official instructions strictly limit the administration of this combination drug to short-term duration, often specified as no longer than 7 days. The drug is designed for the acute, temporary management of cold or flu symptoms, not for chronic therapeutic use.

Q: What are the main things I should discuss with a healthcare provider before starting Recofast PLUS?

Official documentation advises caution for individuals with pre-existing conditions, including severe hypertension, heart disease, glaucoma, diabetes mellitus, hyperthyroidism, and renal or hepatic impairment. These are the types of conditions that are relevant for discussion with a healthcare provider before starting the medication.

Q: Does body weight or mass influence the effect of Recofast PLUS?

Dosing instructions are primarily determined by age group, such as adults and adolescents 12 years. However, dose adjustments based on weight or body mass are sometimes noted for children, and for individuals with established renal or hepatic impairment.

Q: What should I do if a side effect of Recofast PLUS does not go away?

Official documentation advises that if a side effect, such as drowsiness, dizziness, or headache, persists, worsens, or causes concern, the individual is generally advised to consult a healthcare professional. This is the recommended action for persistent, non-serious adverse effects.

How should Recofast PLUS be stored and disposed of?

How to Store and Dispose of Recofast PLUS?

The storage and handling of Recofast PLUS must adhere strictly to the conditions specified on the regulatory label to maintain its stability.

Storage Requirements

Condition Requirement
Temperature Store below 30 C (controlled room temperature).
Protection Keep in a cool, dry place, protected from direct sunlight and moisture.
Container Oral liquid forms must be kept in an airtight container.
Expiry Do not use the medicine after the expiry date has passed.

Storage must include the mandatory child safety measure: keep Recofast PLUS out of the sight and reach of children and pets.

Disposal

Official instructions require patients to talk to a pharmacist about the safe disposal method for unused or expired medication. Disposal must follow local regulations; the product should not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Recofast PLUS found in:

A-Z Index: